Doug Samuelson

Insider activity · 24 months1 buy0 salesCumulative net flow

Nov 24 · 1 buy · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (1 ops.)

€3,582

▼ Sales (1 ops.)

€28k

Latest filing published 26 Nov 2025 for Kairos Pharma, LTD.. Read the official filing

Filing timeline

BuySale

Doug Samuelson

Insider track record

Disclosed buys

Disclosed sells

Signal history

Closed purchases

Market purchases

Not enough history yet: 0 closed purchases, at least 2 are needed.

Purchases by company

Kairos Pharma, LTD. 1 purchase · last 25 Nov 2024

Doug Samuelson: trading record in brief

This profile gathers the share dealings of Doug Samuelson across 2 companies, led by Genelux Corp and Kairos Pharma, Ltd. The record holds 4 filings, for trades running from 17 February 2023 to 8 October 2025.

Market trades split into 1 purchase (€3,582) and 1 sale (€28k). Netting one side against the other leaves €25k of net selling. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 2 share grants.

The latest filing, published on 26 November 2025, reports a share grant in Kairos Pharma, Ltd. The last insider purchase was made public on 25 November 2024, 692 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 27 days. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.